Is therapeutic plasma exchange (PLEX) indicated for yellow phosphorus poisoning, and what are the criteria and recommended protocol?

Therapeutic Plasma Exchange for Yellow Phosphorus Poisoning

In patients with acute liver failure (ALF) from yellow phosphorus poisoning, therapeutic plasma exchange (TPE/PLEX) should be initiated early as it significantly improves transplant-free survival and can serve as a bridge to liver transplantation when needed.

Evidence-Based Recommendation

The most recent and highest quality evidence comes from the 2023 Critical Care Medicine guidelines on ALF management 1, which provides a conditional recommendation for using plasma exchange in critically ill ALF patients who develop hyperammonemia (defined as ammonia >150 μmol/L) 1. However, this guideline addresses hyperammonemia specifically, while yellow phosphorus poisoning presents a broader clinical picture requiring more comprehensive guidance.

When to Initiate PLEX

Start PLEX when ANY of the following criteria are met:

• Acute liver failure develops (coagulopathy with INR >1.5 and any degree of hepatic encephalopathy)
• Hyperammonemia >150 μmol/L 1
• Fulfillment of King's College Hospital Criteria (KCHC) for liver transplantation 2
• Early presentation with significant ingestion (>10 grams consumed) 3

Critical Timing Factors

The evidence strongly indicates that timing is everything:

• Patients who started PLEX within 4.86 ± 1.67 days of ingestion had significantly better outcomes 3
• Early hospitalization (mean 3.6 ± 1.81 days) correlates with recovery 3
• Delay in initiating the procedure is an independent predictor of mortality 4

PLEX Protocol Specifications

Volume and Sessions

Based on the strongest recent evidence 4, 5:

• Low-volume TPE: 1.3-1.5 plasma volumes per session
• Initial course: 3 consecutive daily sessions
• Extended if needed: 3 additional sessions (mean total 3.3 sessions) 3
• Continue until clinical and biochemical improvement occurs

Replacement Fluids

Use a combination approach 4:

• 0.9% normal saline
• 5% human albumin solution
• Fresh frozen plasma (based on ASFA 2019 criteria)

Expected Outcomes

Survival Benefits

The 2024 study 4 demonstrated 68.42% reduction in mortality with LV-TPE compared to controls. Specifically:

• 70% recovery rate in TPE-treated patients 3
• 100% survival in patients NOT meeting KCHC who received TPE 2
• Among KCHC-positive patients: 55% survived (35% without transplant, 20% with transplant) 2

Biochemical Improvements

Expect statistically significant improvements in 4, 5, 2:

• Total bilirubin: decreased from 9.29 to 2.76 mg/dL
• INR: decreased from 2.26 to 1.08
• PT: decreased from 25.5 to 13.3 seconds
• Transaminases: AST from 530 to 53.5 IU/L, ALT from 378 to 54.5 IU/L
• Ammonia levels (particularly in non-KCHC patients)

Predictors of Poor Outcome

Independent mortality predictors requiring aggressive intervention 4:

1. Refractory shock
2. Delay in initiating procedure
3. Acidosis
4. Quantity consumed >10 grams 3

Safety Profile

PLEX is generally safe with manageable adverse events 2:

• Hypotension: 11.62% (managed conservatively)
• Minor allergic reactions: 4.65%
• Line-related complications (minimal with ultrasound guidance)

Clinical Algorithm

For patients presenting with yellow phosphorus ingestion:

1. Immediate assessment (<1 hour):

   • Quantity ingested (>10g = high risk)
   • Time since ingestion
   • Baseline labs: LFTs, INR, PT, ammonia, creatinine

2. If ANY high-risk feature present:

   • Admit to ICU
   • Prepare for PLEX within 24-48 hours
   • Monitor for ALF development

3. Initiate PLEX if:

   • ALF develops (INR >1.5 + encephalopathy)
   • Ammonia >150 μmol/L
   • KCHC criteria met
   • Progressive coagulopathy despite supportive care

4. Continue PLEX until:

   • INR normalizes (<1.5)
   • Bilirubin trending down
   • Clinical improvement evident
   • Minimum 3 sessions completed

Role as Bridge to Transplant

PLEX serves dual purposes 6, 3:

• Definitive therapy in non-KCHC patients (100% survival)
• Bridge to transplantation in KCHC-positive patients, improving pre-transplant condition and extending the window for donor availability

Critical Pitfall to Avoid

Do not withhold PLEX based solely on time since ingestion. Yellow phosphorus can persist in gastric contents beyond 24 hours 7, and the 2021 Liver Transplantation Society of India guidelines 6 specifically recommend considering PLEX regardless of presentation timing when ALF develops. The conventional "1-hour rule" for decontamination does not apply to the decision for PLEX initiation.